Surgical Suction Aspirates Fluorescence Measurement for Glioma Surgery

What this Trial Is About

Gliomas are tumors that can affect people of all ages and represent the most common malignant primary brain tumors in developed countries. They are often aggressive, and surgery combined with chemoradiation is the usual treatment. Complete removal is difficult due to the tumor's diffuse growth and closeness to important brain areas. Surgeons currently use a drug called 5-aminolevulinic acid (5-ALA) that makes tumor cells glow under special light, helping to detect and remove them, but some tumor cells can still be missed, leading to tumor return and additional surgeries. This observational study explores a new medical device that measures fluorescence from the surgical suction waste during glioma surgery. The device's fluorescence detection will be compared to experts' visual assessments of 5-ALA-induced fluorescence seen through an operating microscope. The study includes patients either given 5-ALA before surgery or not, serving as a control group. The device's fluorescence results will not be shared with the surgeon during the operation. Participants will undergo surgery with oral 5-ALA prescribed beforehand when indicated. Researchers will compare fluorescence detected by the device and by the surgeon's visual assessment during surgery, alongside video recordings and tissue analysis results. The study aims to better understand how well the device can detect tumor cells in suction waste. Consent is required, and safety and performance are closely monitored throughout the study period.

Surgical Suction Aspirates Fluorescence Measurement